Skip to main content
. 2019 Dec 16;122(4):506–516. doi: 10.1038/s41416-019-0673-5

Fig. 2. Correlation of response to docetaxel plus selumetinib with MEK 6 gene signature score.

Fig. 2

a Best overall response for patients treated with docetaxel + placebo comparing CR and PR with SD and PD. b Best overall response for patients treated with docetaxel + selumetinib as in (a), *p = 0.026 using one-tailed t test. c Derived benefit for patients treated with docetaxel + placebo comparing benefit with no benefit. d Derived benefit for patients treated with docetaxel + selumetinib as in c, *p = 0.038 using one-tailed t test, testing the pre-established hypothesis that a higher MEK 6 gene score correlates with better clinical outcome when treated with a MEK inhibitor.